Karmanos Cancer Institute to receive first FDA-approved SoftVue system
Forty percent of women have dense breast tissue, putting them at higher risk for breast cancer and making the disease more difficult to detect with a mammogram. A new technology called the SoftVue 3D Whole Breast Ultrasound Technology System can improve screenings for those women. The first FDA-approved unit will be delivered to Karmanos Cancer Institute in just days.